Loading...
•
Dec 31, 2022
Terns Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates.
Key Takeaways
Terns Pharmaceuticals reported its Q4 and full year 2022 financial results. The company's cash and cash equivalents were $283.1 million as of December 31, 2022, expected to provide runway into 2026. Key leadership appointments were announced in oncology R&D and business development.
Cash, cash equivalents and marketable securities were $283.1 million as of December 31, 2022.
R&D expenses were $10.7 million for the quarter ended December 31, 2022.
G&A expenses were $6.2 million for the quarter ended December 31, 2022.
Net loss was $15.8 million for the quarter ended December 31, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...